Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company focused on therapies for rare cardiopulmonary disease, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). News about Liquidia often centers on its treprostinil‑based portfolio, including YUTREPIA™ (treprostinil) inhalation powder, the investigational L606 treprostinil liposome inhalation suspension, and its role in promoting generic Treprostinil Injection in the United States.
On this page, readers can follow company announcements related to YUTREPIA’s commercial launch, prescription trends and patient starts, as well as updates from ongoing clinical programs such as the ASCENT study in PH‑ILD. Liquidia regularly reports interim clinical data, including safety and exploratory efficacy findings, and provides context on how these results may inform treatment of PAH and PH‑ILD.
Investors and observers will also find coverage of quarterly financial results, revenue contributions from YUTREPIA and Treprostinil Injection, and details of corporate developments disclosed in press releases and SEC filings. These include financing arrangements, manufacturing expansion in Morrisville, North Carolina, and licensing agreements such as the exclusive U.S. license with Vectura for a nebulizer device used with L606.
In addition, Liquidia frequently participates in medical and investor conferences, R&D days and scientific meetings, where it presents new data on YUTREPIA and L606 and discusses its strategy in pulmonary hypertension. This news feed helps track how Liquidia advances its PRINT®‑enabled inhaled therapies, navigates litigation and regulatory milestones, and communicates with the medical and investment communities over time.
Liquidia Corporation (NASDAQ: LQDA) will release its third quarter 2022 financial results on November 8, 2022. A conference call and webcast will follow at 8:30 a.m. ET for discussion of the results and corporate updates. Interested parties can join the live call by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international), entering conference code 7467713. Additionally, a webcast will be accessible on Liquidia’s website for 30 days.
Liquidia Corporation (NASDAQ: LQDA) announced that the Precedential Opinion Panel of the USPTO denied United Therapeutics' request to review the PTAB decision that invalidated claims of U.S. Patent No. 10,716,793. The PTAB had ruled the claims unpatentable based on prior art presented by Liquidia. The decision supports Liquidia's position as it seeks final approval for YUTREPIA, its inhalation powder for treating pulmonary arterial hypertension (PAH). CEO Roger Jeffs expressed confidence in the ongoing rehearing process, anticipating a favorable outcome by mid-2024.
Liquidia Corporation (LQDA) announced data presentations for YUTREPIA™ (treprostinil) inhalation powder at the CHEST 2022 Annual Meeting. The data includes findings on higher dose efficacy compared to lower doses and the product's robustness in misuse scenarios. YUTREPIA is designed to treat pulmonary arterial hypertension (PAH) and was granted a tentative FDA approval in November 2021. The presentations will be accessible on the company's website post-event.
Liquidia Corporation (NASDAQ: LQDA) reported a favorable District Court ruling regarding U.S. Patent No. 9,593,066 (‘066 Patent) but an unfavorable outcome for U.S. Patent No. 10,716,793 (‘793 Patent). The court found five of six asserted claims of the ‘066 patent invalid and ruled that the valid claim was not infringed. All claims of the '793 patent were previously invalidated by the PTAB, impacting the FDA approval pathway for YUTREPIA™ (treprostinil) inhalation powder. The company plans to appeal the decision and has scheduled a conference call for September 1, 2022.
Liquidia Corporation (NASDAQ: LQDA) announced the grant of inducement stock options totaling 7,000 shares to newly hired non-executive employees under the 2022 Inducement Plan. Each option is priced at $7.44 per share, the closing price on August 19, 2022. The options have a vesting schedule of four years, with 25% vesting on the first anniversary and the remainder vesting monthly. This grant aligns with Nasdaq Listing Rule 5635(c)(4) to attract new talent. Liquidia focuses on developing products for pulmonary hypertension and other applications of its PRINT® Technology.
Liquidia Corporation (NASDAQ: LQDA) reported its second-quarter financial results for 2022, showing revenues of $3.9 million, up from $3.4 million the previous year. The company has strengthened its financial position with $103.8 million in cash, thanks to a recent equity offering of $54.5 million. Liquidia is focusing on launching YUTREPIA™ inhalation powder, pending regulatory approval, after a favorable ruling in Hatch-Waxman litigation. The company expects to seek a second indication for YUTREPIA in 2024 without additional studies.
Liquidia Corporation (NASDAQ: LQDA) will announce its second quarter 2022 financial results on August 11, 2022, with a conference call scheduled for 8:30 a.m. ET. The call will cover financial results and a corporate update. Interested parties can join by phone or access a webcast, which will be archived for 30 days. Liquidia focuses on developing treatments for pulmonary hypertension, including its inhalation powder YUTREPIA™. For more information, visit Liquidia's website.
Liquidia Corporation (NASDAQ: LQDA) released clinical data from the INSPIRE study on YUTREPIA™ (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH). The study demonstrated effective titration, achieving therapeutic levels within two months, and maintaining safety with primarily mild to moderate side effects. Out of 121 patients, 93% completed the two-month phase, with significant improvement in NYHA functional class. Although the study wasn't designed for definitive efficacy conclusions, preliminary results indicate positive clinical impact. Long-term safety data will continue to emerge from ongoing studies.
Liquidia Corporation (NASDAQ: LQDA) will participate in two upcoming investor conferences: the BTIG Biotechnology Conference 2022 on August 8 in New York, featuring CFO Michael Kaseta's live Fireside Chat at 2:00 p.m., and the Wedbush PacGrow 2022 Healthcare Conference on August 9, a virtual event. The biopharmaceutical firm specializes in pulmonary hypertension treatments, including its product YUTREPIA™ (treprostinil) inhalation powder. More details can be found at www.liquidia.com.
Liquidia Corporation (NASDAQ: LQDA) announced the grant of a stock option for 2,000 shares to a new non-executive employee under its 2022 Inducement Plan. This option is part of the employee's compensation, aligning with Nasdaq Listing Rule 5635(c)(4). The stock option, exercisable at $5.20 per share, has a ten-year term and vests over four years, with 25% vesting after the first year and monthly vesting thereafter. Liquidia focuses on developing products for pulmonary hypertension utilizing its PRINT® Technology.